# US 11,897,964 B2 · Anti-PSGL-1 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,897,964 B2
- Document ID: US11897964B2
- Status: Granted
- Kind: B2
- Application number: 17/460,883
- Filed: 2021-08-30
- Published: 2021-12-23
- Granted: 2024-02-13
- Earliest claimed: 2011-06-13
- Assignees: AltruBio Inc.
- Applicants: AltruBio Inc.
- Inventors: Stefan Bassarab; Barbara Enenkel; Patrick Garidel; Heidrun Schott; Sanjaya Singh; Tobias Litzenburger
- Web page: https://patentgrep.com/patent/US11897964B2

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/53: Hinge
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.

## Claims

### Claim 1

A method for treating graft-versus-host disease (GVHD), psoriatic arthritis, or ulcerative colitis, the method comprising injecting into to a human subject in need thereof a pharmaceutical composition comprising:
(i) a monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:
(a) a light chain comprising a variable light (“VL”) chain region comprising the amino acid sequence of SEQ ID NO: 3;
(b) a heavy chain comprising variable heavy (“VH”) chain region comprising the amino acid sequence of SEQ ID NO: 4; and
(c) a human IgG4 constant region which contains a Serine to Proline substitution at amino acid 228 of the heavy chain numbered according to the EU index; and
(ii) a pharmaceutically acceptable carrier,
wherein, the pharmaceutical composition comprises less than 1% half antibody molecules, wherein upon administration to the subject, the pharmaceutical composition inhibits T-cell mediated inflammation in the subject, and wherein the monoclonal antibody of the pharmaceutical composition administered to the subject is present at a concentration between 0.03 mg/kg and 10 mg/kg.

### Claim 2 (depends on 1)

The method of claim 1, wherein the monoclonal antibody does not interfere with interaction of P-Selectin and PSGL-1 in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the monoclonal antibody of the pharmaceutical composition administered to the subject is present at a concentration selected from 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, and 10 mg/kg.

### Claim 4 (depends on 1)

The method of claim 1, wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 1, and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the light chain consists of the amino acid sequence set forth in SEQ ID NO: 1, and the heavy chain consists of the amino acid sequence set forth in SEQ ID NO: 2.